COLL

Collegium Pharmaceutical Inc

Healthcare, Event Driven/Special Sit


Presented:07/31/2015
Price:$20.03
Cap:$0.15B
Current Price:$38.53
Cap:$1.24B

Presented

Date07/31/2015
Price$20.03
Market Cap$0.15B
Ent ValueN/A
P/E RatioN/A
Book ValueN/A
Div Yield0%
Shares O/S7.55M
Ave Daily Vol113,887
Short Int1.63%

Current

Price$38.53
Market Cap$1.24B
Collegium Pharmaceutical, Inc. a clinical-stage pharmaceutical company, which focuses on the development of proprietary, late stage pharmaceutical products. These products target market opportunities through formulation based product improvements protected by intellectual property. The company builds a portfolio of pain products that incorporate its patent protected DETERx formulation platform that provides for extended release and tamper resistance. Collegium Pharmaceutical was founded by Michael Thomas Heffernan in October 2003 and is headquartered in Canton, MA.

Publicly traded companies mentioned herein: Collegium Pharmaceutical Inc (COLL), Depomed Inc (DEPO), Horizon Pharma PLC (HZNP)

Highlights

Collegium (COLL) recently came public (early May, 2015) and in the presenter’s opinion it stands out as an attractive stock among the plethora of biotech and specialty pharmaceutical companies that have come public over the past year. In the company’s own words, it has “developed a patented, abuse-deterrent technology platform, DETERx, which provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering including crushing, chewing, and heating and injecting”. Its lead product, Xtampza ER, is a tamper resistant oral oxycodone and could be an attractive target. The Phase 3 trial is complete, the NDA has been submitted and accepted, and the PDUFA date is October 12, 2015.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Request access to DeMatteo Research for full access

Request Access

Already have an account?

Idea Discussion

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Idea Discussions display submitted commentary from our investor community.

To read and participate in the discussion with the presenter and investor base, request access to DeMatteo

Request Access

Already have an account?

An error occurred loading this content. Try again later or contact us.